TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
TELA Bio (NASDAQ: TELA) announced that its Compensation Committee approved inducement restricted stock unit grants covering 14,250 shares to five newly hired employees with a grant date of January 20, 2026. The awards were made under the Nasdaq Rule 5635(c)(4) inducement exception as part of each hire's employment compensation. The restricted stock units will vest in equal annual installments over four years, subject to continued service through each vesting date.
Positive
- None.
Negative
- None.
News Market Reaction – TELA
In the Jan 26 session, TELA declined 0.98%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 12 | Inducement grants | Neutral | -1.7% | RSU inducement grants totaling 3,600 shares to new hires over four years. |
| Nov 19 | Conference participation | Neutral | -8.5% | Announcement of participation in Piper Sandler healthcare conference with webcast access. |
| Nov 17 | Inducement grants | Neutral | +14.1% | Nasdaq 5635(c)(4) awards of 30,200 RSUs and 25,000 stock options to new hires. |
| Nov 13 | Equity offering | Negative | -2.6% | Pricing of $13.0M registered direct offering of common stock and pre-funded warrants. |
| Nov 13 | Earnings & financing | Positive | -2.6% | Q3 2025 results with $20.7M revenue, improved losses, and new $70M credit facility. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent TELA headlines show limited price impact from routine items like inducement grants and conferences, while capital-raising and earnings/financing news drew modest negative reactions, except for one positive move on larger inducement/option awards.
Over the last few months, TELA reported several routine and financing-related events. Inducement equity grants under Nasdaq Rule 5635(c)(4) on Nov 10, 2025 and Dec 9, 2025 produced small price moves, indicating such compensation items have not been major catalysts. A conference appearance on Dec 3, 2025 and a $13.0M registered direct offering coincided with negative price reactions. Third quarter 2025 results on Nov 13, 2025, including $20.7M revenue and a new $70M credit facility, also saw a modest decline, suggesting investors remained cautious despite operational progress and added liquidity.
Key Terms
restricted stock units financial
nasdaq rule 5635(c)(4) regulatory
vesting financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 14,250 shares of its common stock to five newly-hired employees, with a grant date of January 20, 2026 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
The restricted stock units will vest in equal annual installments over four years, subject to each individual's continued service with TELA Bio through the applicable vesting dates.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Louisa Smith
ir@telabio.com
